Scripps

Newly published data from Scripps' DETECT study included data from 30,529 device owners, although only 333 of those who were symptomatic also provided their COVID-19 testing results.

Both efforts are employing popular consumer wearables and health trackers to spot potential cases of COVID-19 or other viral diseases as they begin.

By combining prior CDC data with heart rate and sleep measurements, Scripps developed a new disease tracking model that they say could deliver speedy and accurate estimates.

Last year Katherine Kaiser graduated from Stanford University, incidentally meaning she also “graduated” from the Stanford health system.

The results are in for the Scripps Translational Science Institute’s Wired For Health study, and there’s no sugar-coating it: they’re disappointing for those working in digital health.

The Scripps Translational Science Institute is working with Aetna and Johnson & Johnson to launch a trial that will test iRhythm's Zio Patch and the Amiigo activity tracker as possible new ways to screen at-risk populations for atrial fibrillation.

Mountain View, California-based Amiigo, which makes an activity tracker that raised $580,000 on Indiegogo in 2013, has teamed up with online patient community platform Alliance Health to launch a new study looking at the combined effect of wearables and peer support on heart failure patients.

Aliso Viego, California-based Sentrian, the remote patient monitoring company formerly known as Jointly Health, will work with Scripps Translational Science Institute to study its technology on 2,000 patients with COPD.